



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

December 19, 2024

Blaine Davis  
Chief Financial Officer  
Cartesian Therapeutics, Inc.  
7495 New Horizon Way  
Frederick, MD 21703

**Re: Cartesian Therapeutics, Inc.**  
**Registration Statement on Form S-3**  
**Filed December 13, 2024**  
**File No. 333-283803**

Dear Blaine Davis:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Doris Stacey Gama at 202-551-3188 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Sarah Griffiths, Esq.